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Epigenetics provides an important layer of information on top of the DNA sequence 
and is essential for establishing gene expression profiles. Extensive studies have 
shown that nuclear DNA methylation and histone modifications are associated with 
nuclear gene expression levels. However, it remains unclear whether mitochondrial 
DNA (mtDNA) undergoes similar epigenetic changes to regulate the expression of 
mitochondrial genes. Recently, it has been shown that mtDNA is differentially 
methylated in various diseases such as diabetes, colorectal cancer and non-alcoholic 
steatohepatitis. Interestingly, this differential methylation was often associated with 
altered mitochondrial gene expression. However, the direct role of mtDNA methylation 
on mitochondrial gene expression is yet to be ascertained. Alternatively, the activity of 
the mitochondrial transcription factor A (TFAM), a protein involved in mtDNA 
packaging, might influence mitochondrial gene expression. In this review we discuss 
the role of mtDNA methylation and potential epigenetic-like modifications of TFAM with 
respect to mtDNA transcription and replication. We suggest three mechanisms: (1) 
methylation within the non-coding D-loop, (2) methylation at gene start sites (GSS) or 
within gene bodies and (3) post-translational modifications (PTMs) of TFAM. 
Unraveling mitochondrial gene expression regulation could open new therapeutic 















2.1.1 Mitochondrial DNA 
Mitochondria are vital in driving the cell’s metabolic activity as they are responsible for 
producing the bulk of the cell’s energy requirements in the form of ATP, maintaining 
calcium homeostasis and inducing apoptosis 1-3. In the mitochondria, ATP is 
generated through the process of oxidative phosphorylation (OXPHOS), which occurs 
via the electron transport chain (ETC). Interestingly, with the exception of chloroplasts 
in plants, mitochondria are the only organelles that contain their own genome 
(mitochondrial DNA [mtDNA]). Each mitochondrion contains about 1-10 copies of 
mtDNA 4,5. MtDNA is distinctly different from the nuclear DNA (nDNA) (Table 1)6-8. In 
part, this can be explained by the endosymbiotic theory, which states that mitochondria 
evolved from alphaproteobacterium that invaded eukaryotic cells 9-11. Indeed, similar 
to DNA of prokaryotic cells such as bacteria, mtDNA is a circular, double-stranded 
DNA molecule of approximately 16 kb in size 12. The mtDNA comprises a heavy (H) 
strand and a light (L) strand which encode 13 of the polypeptides that constitute the 
Complexes I, III, IV and V of the ETC 13. MtDNA also encodes some of its own 
transcriptional and translational machinery, which includes 22 tRNAs and 2 rRNA 
11,13,14. However, it is important to note that, despite harboring their own genetic 
material mitochondria are heavily dependent on the expression of nDNA which 
encodes the bulk of mitochondrially localized proteins 14. Not much is known about the 
complex coordination that exists between the nucleus and the mitochondria. It is 
known that gene expression in the nDNA is meticulously regulated via different 
mechanisms, including epigenetic modifications, transcriptional and post-
transcriptional regulation. However, it remains elusive whether mtDNA adheres to the 
same principles.   
In this review, we start with an overview of the current evidence supporting the 
presence and functionality of mtDNA methylation and another epigenetic-like 
modification: the PTMs of TFAM. Subsequently, we will highlight studies in which 
differential mtDNA methylation was reported to occur in diseases. Finally, based on 
the literature reviewed, we put forward hypotheses on how these phenomena may 
contribute to mtDNA replication and transcription.     
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Table 1. Differences between human nuclear DNA and mitochondrial DNA  
Feature Nuclear DNA Mitochondrial DNA 
Size (in bp) ~3 x 109  16,569  
Shape Linear double helix Circular double helix 
Inheritance Both parents Maternal 
DNA copies/cell 2 ~10-50,000 
Number of genes ~20,000 protein coding 13 protein-coding + 24 non-protein 
coding 
Gene density ~1 in 40,000 bp 1 in 450 bp 
Introns Found in almost every gene Absent 
% coding DNA ~3% ~93% 
Histones Associated with the DNA Not associated with the DNA 
CpG islands 24,000-27,000 None 
CpG density 1% 2.6% 
Methylation Present (3-4% of all Cs [~70-
80% of all CpGs]) (mainly 
CpG) 
Present (~1.5-5% of all Cs)  
(both CpG and CnonG) 
Hydroxymethylation Present (0.03-0.69% of all 
Cs) 
Present                                             
6-8 
 
2.1.2 MtDNA transcription and replication  
Before we discuss how mtDNA methylation may influence mtDNA transcription and 
replication, we will first explain what is already known about these processes in 
mitochondria. Unlike the nDNA, which contains at least one promoter region per gene, 
the mtDNA contains only three promoter regions that transcribe multiple genes at once 
to produce polycistronic transcripts. The L-strand is transcribed from the L-strand 
promoter (LSP), whereas the H-strand is transcribed from the H-strand promoters 1 
and 2 (HSP1, HSP2) (Figure 1). The HSP1 enables the transcription of 12S and 16S 
ribosomal RNAs while the HSP2 promotes transcription of the entire H-strand as a 
polycistronic transcript (see Figure 1)  15. For transcription the mitochondrial RNA 





adenosine transferase 2, mitochondrial protein (TFB2M) assemble at the promoters 
to initiate the synthesis of polycistronic RNAs that are later processed into single 
mRNAs 16,17.  These promoters are located within or in the vicinity of a 1 kb locus, 
known as the mitochondrial displacement loop (D-loop) or mtDNA non-coding region 
(NCR).Besides the promoters, the D-loop also contains the origin of replication of the 
H-strand (OH). The L-strand origin of replication (OL) lies outside the D-loop (see 
Figure 1). The D-loop has a peculiar triple helix structure consisting of the L- and H- 
strand plus an additional 7S DNA primer, which forms the third nascent DNA strand 
13. The replication of mtDNA is a rather complex process and three models have been 
proposed to explain the mechanism of mtDNA replication (Reviewed by Holt et al., 
and Nicholls, et al.,) 13,17. In one of the models, it is hypothesized that the 7S DNA may 
play a pivotal role in mtDNA replication. Herein, according to this model, H-strand 
replication is initiated at the LSP leading to the synthesis of 7S RNA 13,18. In the 
presence of the mitochondrial DNA polymerase-gamma (POLG), the newly-formed 7S 
RNA then primes the synthesis of the H-strand 13,18. Even though the functions of the 
D-loop are still under debate, it is widely accepted that this structure facilitates mtDNA 
replication by maintaining an open structure 18. This makes the D-loop a likely 
candidate for epigenetic modifications, which can also have a major impact on the 






Table 1. Differences between human nuclear DNA and mitochondrial DNA  
Feature Nuclear DNA Mitochondrial DNA 
Size (in bp) ~3 x 109  16,569  
Shape Linear double helix Circular double helix 
Inheritance Both parents Maternal 
DNA copies/cell 2 ~10-50,000 
Number of genes ~20,000 protein coding 13 protein-coding + 24 non-protein 
coding 
Gene density ~1 in 40,000 bp 1 in 450 bp 
Introns Found in almost every gene Absent 
% coding DNA ~3% ~93% 
Histones Associated with the DNA Not associated with the DNA 
CpG islands 24,000-27,000 None 
CpG density 1% 2.6% 
Methylation Present (3-4% of all Cs [~70-
80% of all CpGs]) (mainly 
CpG) 
Present (~1.5-5% of all Cs)  
(both CpG and CnonG) 
Hydroxymethylation Present (0.03-0.69% of all 
Cs) 
Present                                             
6-8 
 
2.1.2 MtDNA transcription and replication  
Before we discuss how mtDNA methylation may influence mtDNA transcription and 
replication, we will first explain what is already known about these processes in 
mitochondria. Unlike the nDNA, which contains at least one promoter region per gene, 
the mtDNA contains only three promoter regions that transcribe multiple genes at once 
to produce polycistronic transcripts. The L-strand is transcribed from the L-strand 
promoter (LSP), whereas the H-strand is transcribed from the H-strand promoters 1 
and 2 (HSP1, HSP2) (Figure 1). The HSP1 enables the transcription of 12S and 16S 
ribosomal RNAs while the HSP2 promotes transcription of the entire H-strand as a 
polycistronic transcript (see Figure 1)  15. For transcription the mitochondrial RNA 





adenosine transferase 2, mitochondrial protein (TFB2M) assemble at the promoters 
to initiate the synthesis of polycistronic RNAs that are later processed into single 
mRNAs 16,17.  These promoters are located within or in the vicinity of a 1 kb locus, 
known as the mitochondrial displacement loop (D-loop) or mtDNA non-coding region 
(NCR).Besides the promoters, the D-loop also contains the origin of replication of the 
H-strand (OH). The L-strand origin of replication (OL) lies outside the D-loop (see 
Figure 1). The D-loop has a peculiar triple helix structure consisting of the L- and H- 
strand plus an additional 7S DNA primer, which forms the third nascent DNA strand 
13. The replication of mtDNA is a rather complex process and three models have been 
proposed to explain the mechanism of mtDNA replication (Reviewed by Holt et al., 
and Nicholls, et al.,) 13,17. In one of the models, it is hypothesized that the 7S DNA may 
play a pivotal role in mtDNA replication. Herein, according to this model, H-strand 
replication is initiated at the LSP leading to the synthesis of 7S RNA 13,18. In the 
presence of the mitochondrial DNA polymerase-gamma (POLG), the newly-formed 7S 
RNA then primes the synthesis of the H-strand 13,18. Even though the functions of the 
D-loop are still under debate, it is widely accepted that this structure facilitates mtDNA 
replication by maintaining an open structure 18. This makes the D-loop a likely 
candidate for epigenetic modifications, which can also have a major impact on the 







Figure 1: Simplified diagram of human mitochondrial DNA 
2.2. Epigenetics and DNA methylation 
Epigenetics refers to the heritable changes in gene expression that do not involve 
alteration of the DNA sequence itself. As such, epigenetics provides the basis 
explaining why different cell types have different gene expression profiles have despite 
having the same genetic material. There are various mechanisms by which epigenetic 
gene expression regulation can be achieved and these involve covalent modifications 
of either the DNA or proteins associated with the DNA, that is, histones in the case of 
nDNA, which may influence chromatin remodeling. The field of epigenetics has rapidly 
evolved over the past 50 years with the development of robust, single base-pair 
resolution techniques, such as whole genome sequencing, to study this phenomenon 
19.             
DNA methylation involves the addition of a methyl group on the cytosine base giving 
rise to 5-methylcytosine (5mC).  In mammalian nDNA, 5mC frequently occurs on CpG 
sites (cytosine base preceding a guanine base). Furthermore, these CpG sites 





known as “CpG islands” 20. Interestingly, while hypermethylation within promoter 
regions has been shown to correlate with low gene expression, methylation within 
gene bodies is associated with actively transcribed genes 21. During early embryonic 
development, CpG methylation patterns are formed by the de novo 
methyltransferases, DNMT3A and DNMT3B, whereas maintenance of these 
methylation patterns is carried out by the maintenance methyltransferase, DNMT1. 
Moreover, in some cases, DNA also undergoes demethylation, which can occur either 
passively during DNA replication when maintenance methylation by DNMT1 fails or 
actively by the action of Ten-eleven translocation (TET) enzymes 22. TET-induced 
DNA demethylation occurs through the interesting, yet less well studied, DNA 
modifications, 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). 
3. IS MITOCHONDRIAL GENE EXPRESSION REGULATED BY A 
MITOCHONDRIAL EPIGENETIC LAYER? 
3.1. The presence of mtDNA methylation  
One of the leading questions with respect to the regulation of mitochondrial gene 
expression is whether epigenetic-like phenomena are present on the mtDNA and if 
such mechanisms indeed affect mitochondrial gene expression. To date, controversy 
still surrounds the notion of mtDNA methylation (Table 2). The discovery of the 
mitochondrial-localized DNA methyltransferase 1 (mtDNMT1) and the presence of 
mtDNA methylation by Shock, et al., 23 sparked the debate on the role of methylation 
and epigenetic-like mechanisms in regulating mitochondrial gene expression. Indeed, 
the discovery of the mtDNMT1 suggests that mtDNA undergoes methylation, contrary 
to earlier studies that disputed mtDNA methylation (see Table 2). The debate on the 
existence of mtDNA methylation stems from the early studies, which observed only 
low levels (<5%) of methylation 24-27, if any at all 28-30. It was unclear whether the 
observed methylation was merely an artefact, arising from the incomplete separation 
of the mitochondrial DNA from the nuclear DNA or whether the absence of methylation 
was a consequence of the use of insensitive detection techniques 19. Interestingly, 
recent advanced single base pair resolution sequencing studies showed compelling 
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mtDNA (see section 4, Table 2 and reviews by Manev et al., 2012 and van der Wijst 
et al., 2015 19,31).   
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The absence of CpG islands in mtDNA is a strong argument that has been used to 
refute the idea that mtDNA undergoes functional methylation. Intriguingly, studies 
have shown that despite the absence of CpG islands, methylation within the D-loop 
and other loci within the mtDNA correlates with the expression of mitochondrial genes 
32,33. Besides CpG methylation, it has also been shown that mtDNA exhibits a peculiar 
non-CpG methylation pattern (CpC, CpA and CpT) which is characteristic of 
prokaryotic genomes such as those of bacteria 7,12. In essence, this points to the fact 
that methylation (5mC and 5hmC, CpG and non-CpG) occurs within the mtDNA.  






3.2. Specific subregions with importance for functional methylation 
The mitochondrial D-loop is unarguably one of the most important regions on the 
mtDNA due to its central role in transcription and replication. Apart from housing the 
promoters (LSP, HSP1 and HSP2), the D-loop also contains three conserved 
sequence blocks (CSB I, CSBII and CSBIII). Of these three CSBs, it has been reported 
that CBSII is particularly important for transcription termination and 7S DNA primer 
formation 34. Differential methylation within the D-loop has been reported in many 
studies now although none have been able to ascribe a precise function for it 7,18,35,36. 
Since the D-loop plays an important role in mtDNA replication and transcription, it is 
likely that methylation of this region would influence mtDNA gene expression, either 
directly or indirectly, via modulation of the mtDNA copy number (Figure 2). A recent 
study by Bianchessi et al., 18 described D-loop methylation in replicative and senescent 
endothelial cells (ECs) and identified an uneven distribution of 5mC (both CpG and 
non-CpG) between the L-strand and the H-strand. Moreover, they found that 
methylated sites within the D-loop have a tendency to form clusters. Interestingly, on 
average, the frequency of methylation on the H-strand was found double compared to 
the L-strand. These findings concur with an earlier study by Bellizzi et al., 7 
demonstrating that non-CpG methylation frequently occurs within CSBs. However, 
these two studies disagree as Bianchessi observed that CpA methylation occurs most 
frequently and CpC methylation occurs the least whereas Bellizzi reported that CpC 
methylation is dominant. Moreover, Bellizzi only detected methylation at the L-strand 
and not on the H-strand. In contrast, several studies have shown that both strands are 
methylated within the D-loop 18,32,35,37. In retrospect, these differences may have arisen 
from the different species or cell types that have been used for the various studies. It 
is interesting to see whether the presence of non-CpG methylation within CSBs affects 
7S DNA formation, which in turn may affect mtDNA replication.     
Next to 5mC, also 5hmC was reported to be present in the mitochondrial DNA 6,7,23,38. 
In two recent studies by Ghosh et al., it was shown that 5mC marks are enriched in 
regions upstream of the gene start site (GSS) and within gene bodies while 5hmC 
marks cluster near the GSS rather than in the coding regions (gene bodies) of 
mitochondrial encoded genes  6,38. Furthermore, in one of the studies they analyzed 
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across GSSs correlates with the development stage of the brain 38. Indeed, this spells 
out a possible epigenetic function of GSS methylation. However, the presence of 
5hmC around the GSS did not correlate with gene expression 6. This leaves 5mC as 
the most likely candidate to test whether GSS methylation influences gene expression. 
Apart from D-loop and GSSs, gene bodies might be important subregions where 
methylation may have a profound effect on gene expression. In the nDNA, it is known 
that 5mC in gene bodies is associated with actively transcribed genes 21. In mtDNA, 
differential gene body methylation, mostly 5mC, has indeed been shown to correlate 
with changes in mitochondrial gene expression and the progression of diseases such 
as non-alcoholic steatohepatitis (NASH) (see 4.1).  
3.3. The role of TFAM and other proteins directly associated with mtDNA 
For nDNA, histone modifications are important epigenetic mechanisms that influence 
gene expression. However, in the mitochondria, histones are not associated with 
mtDNA and therefore mtDNA cannot undergo histone-mediated gene expression 
regulation 39. Interestingly, despite lacking histone proteins, the mtDNA is not naked; 
the mtDNA is clustered in protein-DNA complexes called nucleoids, of which the main 
constituent, TFAM, is thought to entirely coat the mtDNA 5,40. TFAM is a versatile 
protein located in the mitochondrial matrix and it is thought to have a histone-like 
function 40. It is responsible for packaging and organizing the protein-mtDNA complex 
5,40,41, a role that is played by histones in the nucleus. In addition to packaging the 
mtDNA, experimental evidence shows that TFAM promotes the replication, 
transcription and general maintenance of mtDNA 42. It binds mtDNA to initiate the 
transcription at the LSP and HSP1. On the other hand, it has been shown that HSP2 
transcription is independent of TFAM, but rather depends on POLRMT and TFB2M 43. 
However, it has been described that TFAM has a dual function on HSP2 whereby it 
can activate or repress HSP2 transcription depending on the TFAM: TFB2M/POLRMT 
ratio 43,44. TFAM appears to competitively repress HSP2, but its activity is diminished 
when the concentrations of TFB2M and POLRMT are high44. In addition, Ngo and 
colleagues observed that the binding of TFAM to mtDNA generated a U-shaped bend, 
which is essential for both mtDNA compaction and transcriptional activation 40. 
Moreover, it has been shown that the accessibility of different sites on the mtDNA 





are less accessible to DNMTs and hence they are difficult to methylate 45. This 
suggests that TFAM activity plays a role in determining the methylation pattern of 
mtDNA. Therefore, it is plausible that PTMs of TFAM may alter its binding to mtDNA, 
and thus, indirectly alter the methylation status of the mtDNA.    
In the nDNA, histone PTMs, such as acetylation and methylation, are important in 
epigenetic regulation of gene expression by changing the chromatin state (open 
versus closed). Interestingly, PTMs such as acetylation, phosphorylation and 
ubiquitination have been reported for TFAM 46-48. Of these three PTMs, TFAM 
phosphorylation has indeed been shown to impair TFAM binding activity. 
Unfortunately, the study did not assess the effects of TFAM phosphorylation on 
mitochondrial gene expression 48.This brings into question, whether TFAM 
phosphorylation or any other PTM actually has an influence on TFAM activity, 
translating to modulation of gene expression. Besides TFAM, other important factors 
that are associated with nucleoids include the POLG, the mitochondrial DNA helicase 
Twinkle and the mitochondrial single-stranded DNA binding protein (mtSSB). While 
TFAM is involved in both mtDNA transcription and replication, POLG, Twinkle and 
mtSSB are thought to be only involved in mtDNA replication 49-51. Due to its versatile 
functions, TFAM appears to be the most prominent mitochondrial protein whose 
activity may greatly influence mitochondrial gene expression.   
4. DISEASES AND CONDITIONS ASSOCIATED WITH DIFFERENTIAL MTDNA 
METHYLATION 
Recent studies, as described in more detail below (4.1-4.5), report an increasing 
number of diseases and conditions associated with changes in mtDNA methylation at 
various loci. This brings about the important question whether changes in mtDNA 
methylation are the cause for a disease or are a mere consequence of these diseases 
and whether this acts through gene expression regulation. At this stage it appears 
prudent to ask the question: does mtDNA methylation serve any purpose? In this 
respect, it is of importance to note that some studies have not been able to observe 
any correlation between differential mtDNA methylation and disease (see Table 2). 
Below, we highlight the diseases for which differential mtDNA methylation was 
reported and which thus might serve as model diseases to unravel the functional role 
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4.1. Metabolic disorders 
Obesity, a leading metabolic disorder in developed countries, is associated with a 
higher risk of developing type II diabetes 52,53. Understanding the different mechanisms 
that drive this intricate relationship is important to shed light on how metabolic 
disorders develop. Recently, a study showed that insulin signaling influences mtDNA 
methylation in obese human subjects 36. Increases in mtDNA methylation at the D-
loop were strongly associated with obesity (5.2-fold increase compared to lean 
controls) and insulin resistance (4.6-fold increase compared to insulin sensitive 
controls). Interestingly, the level of methylation increased at the D-loop region only 
and, importantly, this correlated with a decrease in mtDNA copy number. A general 
assumption with regard to the decrease in mtDNA copy number is that it can have an 
overall effect on mitochondrial gene expression and therefore lead to mitochondrial 
dysfunction 54. From this study, it thus appears that D-loop methylation correlates with 
a decrease in mtDNA copy number, which may result in an overall cellular decrease 
of mitochondrial gene expression.       
In addition, obese individuals are prone to liver diseases such as NASH 55,56. NASH is 
characterized by triglyceride accumulation, hepatocellular damage and inflammation. 
Mitochondrial dysfunction contributes to the development of NASH due to disruption 
of lipid metabolism in the mitochondria. Recently it has been reported that mtDNA 
aggravates inflammation in NASH patients by activating the toll-like receptor 9 (TLR9) 
pathway 57. Interestingly, a study by Pirola and colleagues showed that the MT-ND6 
region is about 20% more methylated in NASH patients compared to the patients who 
are at the initial stages of the disease. Importantly, an increase in MT-ND6 methylation 
correlated with a decrease (>50%) in MT-ND6 mRNA and protein expression 33. 
Methylation was also measured in the D-loop and MT-COI but, although methylation 
could be detected in both diseased and healthy samples, these profiles did not 
correlate with NASH. The increase in methylation within the MT-ND6 gene body was 
associated with progression of the disease condition. The ND6 protein is a subunit of 
the mitochondrial complex I, which is a vital component of the electron transport chain 
(ETC) during ATP production. As such, a change in MT-ND6 expression may 
negatively impact on mitochondrial function, which includes lipid metabolism, and thus, 





respect to gene body methylation and gene expression regulation whereby 
methylation prevents gene transcription. This is contrary to the widely accepted notion 
for nDNA where gene body methylation is associated with actively transcribed genes 
21. However, it is important to note that the effect of methylation on gene expression 
might have been an indirect effect.  
4.2. Neurodegenerative diseases (Down Syndrome, Alzheimer and Parkinson’s 
disease) 
In Down syndrome (DS) patients, the DNA methylome is known to be disturbed; in the 
nuclear genomes of DS subjects, global hypermethylation is observed 58-60, whereas 
the mitochondrial genomes are hypomethylated 58. Interestingly, DS patients have 
been shown to harbor a higher risk of developing early onset Alzheimer’s disease 
(AD). Mitochondrial dysfunction has been shown to correlate with the development of 
neurodegenerative disorders, such as AD and Parkinson’s disease (PD). A recent 
study was carried out using postmortem brain tissue from AD patients 37. In this study, 
only the D-loop was analyzed for methylation and it was observed that both CpG and 
non-CpG sites in the entorhinal cortex and substantia nigra of patients are methylated, 
whereas the authors could not detect methylation for healthy controls. In mouse 
models of AD, these dynamic methylation patterns were also observed. Interestingly, 
contrary to the observations in AD, the authors detected that the D-loop in a mouse 
PD model was not methylated in nearly all CpG and non-CpG sites. From these two 
contrasting observations it appears that mtDNA is differentially methylated depending 
on the disease. Mitochondrial dysfunction in neuronal tissue is associated with 
neurodegenerative diseases, hence, any factor that contributes to this dysfunction 
might have a key role in the disease initiation and progression. If mtDNA methylation 
has an effect on mitochondrial function then this propels it up as a potential candidate 
in the etiology and therapy of neurodegenerative diseases.  
4.3. Colorectal cancer 
Differential mtDNA methylation was recently reported for colorectal cancer in two 
studies by Feng et al., 35,61. In both studies, progressive hypomethylation of the D-loop 
was observed in colorectal cancer patients and this corresponded with an increase in 
mitochondrial MT-ND2 expression. Intriguingly, in both cohorts, the D-loop methylation 
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cancer patients (11.4% and 13.8%). In both studies, the demethylation of the D-loop 
was associated with increased expression of MT-ND2 and an increased mtDNA copy 
number during both the initial stages of colorectal cancer as well as during its 
progression 35,61. In a letter to the editor, Maekawa and colleagues reported absence 
of mtDNA methylation in the MT-RNR2, MT-COI and MT-COII loci in 15 cancer cell 
lines and in tissues (both malignant and healthy) from 32 patients with gastric cancer 
and 25 patients with colorectal cancer 29. However, it is important to note that in this 
study, methylation within the D-loop was not assessed, nor mitochondrial gene 
expression levels. The data provided in these studies suggests that colorectal cancer 
may be associated with differential D-loop methylation, which affects gene expression 
similarly as in the nDNA. However, it still leaves some questions unanswered with 
regard to whether the changes in gene expression are a direct or indirect effect of D-
loop methylation. As described earlier, the D-loop acts as the control region of the 
mtDNA where polycistronic transcription of the mtDNA is initiated. Based on this 
polycistronic transcription, altered gene expression would have been expected to 
occur on all the H-strand encoded genes. Unfortunately, in these studies, expression 
of other mitochondrial genes was not measured. 
4.4. Cardio-vascular diseases 
Recently it was shown that platelet-derived mtDNA is hypermethylated in 
cardiovascular disease (CVD) patients compared the healthy controls, regardless of 
their age, race or BMI 62. Unlike most studies where researchers focus on the 
methylation state of the D-loop, the CVD study looked at methylation patterns within 
gene bodies. Significantly high levels of mtDNA methylation were only observed for 
MT-COI (18.53%), MT-COII (3.33%), MT-COIII (0.92%), and MT-TL1 (1.67%) in 
patients with CVD compared to the healthy controls 62. The occurrence of methylation 
within gene bodies suggests a potential mechanism of regulating gene expression in 
mtDNA, as was observed before in the MT-ND6 locus of NASH patients.  Based on 
the existing evidence, methylation of the mtDNA appears to somehow affect the 








Mitochondria have been implicated in many studies as major drivers of the aging 
process . In light of this notion, hypotheses such as the free radical theory, rate of 
living theory and mtDNA mutations hypothesis have been proposed to explain the role 
of mitochondria in aging. In a recent study, it was observed that two CpG sites located 
within the 12S ribosomal RNA gene (MT-RNR1) are differentially methylated and this 
correlates with aging 63. This study confirms a previous study by D’Aquila et al, where 
they checked for methylation in  MT-RNR1 and  MT-RNR2. In this study, mtDNA 
methylation levels up to 10% were observed within the MT-RNR1 and this correlated 
with the age of the patients. Based on differential methylation within this gene, the age 
of 64.5% of patient samples was correctly predicted using a linear regression 
prediction model 64.Apart from being used as a marker for aging, methylation of mtDNA 
may provide new insights into the mechanisms that drive the aging process.  However, 
it can be argued that as people age there is a manifestation of various diseases and 
conditions that may influence the mtDNA methylation state. Therefore, it is important 
to always include age-matched controls for disease association studies to avoid bias. 
5. MTDNA METHYLATION AND DISEASES, A CAUSE OR CONSEQUENCE? 
The examples described in section 4 indicate interesting associations between mtDNA 
methylation and disease, but the functional role of mtDNA methylation in the 
development of diseases remains an open question. The underlying question is 
whether mtDNA methylation contributes to gene expression dysregulation? While 
some studies open exciting options for mtDNA to be further explored as mechanisms 
underlying the “cause” of a disease, it is also possible that mtDNA methylation might 
be a mere consequence of the disease arising from the dysregulation of many vital 
metabolic pathways. According to the few epigenome association studies that have 
been reported on mtDNA methylation to date, the correlation between metabolic 
diseases (e.g., diabetes, NASH) and mtDNA methylation highlights its probable impact 
on metabolic pathways and/or vice versa. One of the pitfalls in studies aimed at 
deciphering the functional relevance of mtDNA methylation is the heteroplasmic nature 
of mtDNA. While methylation may be present at a particular location on a single 
mtDNA molecule, the probability that all the mtDNA molecules in the cell will have the 
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be a mere consequence of the disease arising from the dysregulation of many vital 
metabolic pathways. According to the few epigenome association studies that have 
been reported on mtDNA methylation to date, the correlation between metabolic 
diseases (e.g., diabetes, NASH) and mtDNA methylation highlights its probable impact 
on metabolic pathways and/or vice versa. One of the pitfalls in studies aimed at 
deciphering the functional relevance of mtDNA methylation is the heteroplasmic nature 
of mtDNA. While methylation may be present at a particular location on a single 
mtDNA molecule, the probability that all the mtDNA molecules in the cell will have the 






thresh-hold above which methylation has a noticeable effect on mitochondrial function 
and or gene expression. Existing data suggests that mtDNA methylation may be linked 
to mitochondrial gene expression via one of at least three mechanisms: methylation 
within the D-loop, methylation at the GSSs or within gene bodies and post-translational 
modifications of TFAM.         
Differential methylation within the mitochondrial D-loop correlates with different 
diseases and is associated with changes in mtDNA copy number 35-37,61. It is possible 
that D-loop methylation may influence mitochondrial gene expression either directly 
by altering mtDNA transcription, or indirectly by modulating mtDNA copy number. It 
can be hypothesized that via the regulation of TFAM binding to promoter regions, D-
loop methylation may alter transcription. Moreover, any factor that modulates  mtDNA 
copy number might indirectly influence gene expression (Figure 2) 54. An example of 
such a factor that may be influenced by D-loop methylation and may alter mtDNA copy 
number is the 7S DNA primer, as suggested by Bianchessi et al., 18. On the other 
hand, methylation on GSSs and gene bodies may potentially influence gene 
expression by affecting gene splicing. For instance, in nDNA, it has been reported that 
methylation within exons and splice sites regulates alternative splicing of mRNA 
precursors 65. This may be an alternative function for GSSs and gene body 
methylation, although the absence of introns in mtDNA makes it less probable to 
undergo alternative splicing. However, based on evidence showing that mtDNA gene 
body methylation in some diseases correlates with altered gene expression it is 
possible that the polycistronic mitochondrial mRNA precursor undergoes unknown 
post-transcriptional modifications to influence gene expression.   
    
TFAM binding to the mtDNA appears to play a crucial role in determining the 
accessibility of mitochondrial genes for other proteins by modulating mtDNA 
compaction. In the nDNA, compact heterochromatin is associated with repressed 
genes.  This may be true for the mtDNA as well, whereby high levels of TFAM binding 
to the mtDNA are characteristic of compact mtDNA. There is indeed evidence that 
higher levels of TFAM increase mtDNA compaction and prevent methylation of CpG 
sites 40,45. PTMs of TFAM may influence its binding to the mtDNA and as a 





replication. Together with TFB2M and POLRMT, TFAM is an important player in 
mtDNA transcription. Therefore, proteomic studies aiming at assessing the interaction 
between post-translationally modified TFAM and these other proteins may reveal 
undiscovered pathways by which TFAM may influence mitochondrial gene expression. 
Figure 2: Proposed mechanisms of epigenetic regulation of mitochondrial gene expression 
 
6. FUTURE PERSPECTIVES 
To date, we have only scratched the surface of the topic on mitochondrial epigenetics 
and mitochondrial gene expression regulation. Whether mtDNA methylation 
contributes to disease pathogenesis by altering gene expression directly or indirectly 
remains a biological enigma that resembles the “chicken and egg” conundrum. As the 
debate rages on, it is important to understand the mechanisms that regulate 
transcription of mitochondrial genes. This assessment should take into account all 
epigenetic-like modifications on the mtDNA and its associated proteins.  At present, 
even with the increasing number of studies on mtDNA methylation, it is difficult to attest 
that mtDNA methylation has a direct effect on gene expression. There is no clear 
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from the association studies that have been carried out. However, taking into account 
the increasing evidence that supports the notion that mtDNA methylation correlates 
with gene expression, there is need to further test this hypothesis. In this respect, 
epigenetic editing provides potent tools to test whether mtDNA methylation influences 
gene expression 66,67. Indeed, the mitochondrial targeting of epigenetic enzymes fused 
to DNA binding domains designed to bind a mtDNA locus of interest could unravel the 
actual effects of methylation on gene expression. If indeed mtDNA methylation has a 
profound effect on the expression of mitochondrial genes then its role in the 
development of different diseases could be clearly defined. Moreover, the reversibility 
of DNA methylation presents an opportunity for the discovery of novel drug 
interventions to treat diseases associated with mtDNA methylation. Unravelling the 
function of mtDNA methylation and other epigenetic-like phenomena, such as TFAM 
phosphorylation and acetylation, may open new insights in the field of mitochondrial 
epigenetics, which could further aid in drug discovery directed to prevent or even treat 
the wide variety of diseases, known to be associated with dysfunctional mitochondria.  
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